Scarica l'app Stockscreener
20.65
4.93%
0.97
Dopo l'orario di chiusura:
20.80
0.15
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$19.68
Aprire:
$18.922
Volume 24 ore:
1.63M
Relative Volume:
0.93
Capitalizzazione di mercato:
$3.27B
Reddito:
$1.27M
Utile/perdita netta:
$-512.54M
Rapporto P/E:
-6.955
EPS:
-2.9691
Flusso di cassa netto:
$-422.10M
1 W Prestazione:
+4.64%
1M Prestazione:
-1.67%
6M Prestazione:
+35.86%
1 anno Prestazione:
+50.29%
Intervallo 1D:
$18.92
$20.66
Intervallo di 1 settimana:
$17.86
$20.66
Portata 52W:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8547
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.65 | 3.27B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-04-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNLI Technical Analysis & Stock Price Forecast - intellectia.ai
Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance Singapore
Denali Regains DNL593 Rights After Takeda Collaboration Ends - TipRanks
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration - TradingView
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593 - MarketScreener
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug - Stock Titan
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - The Manila Times
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Aug Opening: Is Denali Therapeutics Inc a turnaround storyQuarterly Market Review & Community Verified Trade Alerts - baoquankhu1.vn
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Market Overview: Will Denali Therapeutics Inc outperform small cap indexesQuarterly Market Review & Weekly High Return Opportunities - baoquankhu1.vn
Pullback Watch: Will Denali Therapeutics Inc benefit from government policy2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - minichart.com.sg
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks
Denali Therapeutics receives $200 million from royalty agreement after FDA approval - Investing.com India
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA NodWhat's Changed - finance.yahoo.com
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition? - simplywall.st
(DNLI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter SyndromeSlideshow (NASDAQ:DNLI) 2026-03-27 - Seeking Alpha
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright - Defense World
(DNLI.O) | Stock Price & Latest News - Reuters
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs - MedCity News
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI) - Stock Titan
Denali Receives FDA Approval for Hunter Syndrome Treatment, Shares Rise - Bitget
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7%Time to Sell? - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 By Investing.com - Investing.com Australia
The Goldman Sachs Group Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 - Investing.com UK
Denali Therapeutics (DNLI) Receives Analyst Rating Update from B - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Benzinga
Some 13 years and $2 billion later, Denali Therapeutics wins first drug approvalSan Francisco Business Times - The Business Journals
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod - BioSpace
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH By Investing.com - Investing.com Australia
FDA approves drug to treat neurologic manifestations of Hunter syndrome - The Pharma Letter
Denali gains on FDA approval of lead asset - MSN
Stifel raises Denali Therapeutics price target on drug approval By Investing.com - au.investing.com
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - BioSpace
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):